TELOGENOMICS

Corporate Update

Transforming Cancer Diagnostic with AI and Liquid Biopsy

TSXV: TELO | OTCQB: TDSGF
https://www.telodx.com

Forward Looking Statement & Disclosures

This document and any attachments are intended for information purposes only and should not be construed as on offer or solicitation for the sale of securities. Statements in this presentation include forward-looking statements within the meaning of certain securities laws. These forward-looking statements include, among others, statements with respect to our objectives, goals and strategies to achieve those objectives and goals, as well as statements with respect to our beliefs, plans, objectives, expectations, anticipations, estimates and intentions. The words “expected to” “illustrate” “has the potential to” “will be”, “evaluating” “plans” “can be” “planning” “to predict” “potential” “may” “should” and words and expressions of similar import, are intended to identify forward-looking statements. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not put undue reliance on these statements, or the scientific data presented as a number of important factors, many of which are beyond our control, could cause our actual results to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates and intentions expressed in such forward-looking statements. We do not undertake to update any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf; such statements speak only as of the date made. The forward-looking statements included herein are expressly qualified in their entirety by this cautionary language.

MRD - The Key to Staying a Step Ahead of Cancer

Too late, too often: **Telo Genomics Minimal Residual Disease (MRD) test makes cancer detection faster and sharper.**

- ***Late detection of relapse***
- ***Overtreatment and undertreatment***
- ***Uncertainty in prognosis***
- ***Slow and costly drug development***

Telo Genomics' proprietary 3D telomere platform directly addresses key limitations in current oncology care and drug development

Why Invest in Telo Genomics?

Clinically Validated & De-Risked

Backed by studies in over 3,000 patients, 190+ publications – across oncology and CNS (Alzheimer's)

Breakthrough AI + Telomere Technology

First and only platform using telomere architecture + AI to detect aggressive cancer cells, in addition to counting them

Game-Changer in MRD Detection

Up to 100× more sensitive than current technologies — detects relapse earlier, differentiates aggressive vs benign residual disease.

Poised for Commercialization

CLIA/CAP certification in progress – anticipated in 2025

Oncology and CNS diagnostics address $55B+ markets

Telo Genomics Will Disrupt the MRD Business

Telo Genomics MRD: Delivering Superior Sensitivity in Blood-Based Cancer Monitoring and Aggressive Cell Detection

>$30M Canadian Grant Funding + $20M investment funding

Clinically Proven – *Validated by top-tier U.S. cancer centers*

Dana-Farber Cancer Institute

MAYO CLINIC

Liquid Biopsy Platform – *Non-invasive, scalable tool for therapy monitoring across many cancers*

AI-Driven First-Mover – *Only company applying AI to telomere-based cancer cell identification*

MRD Expansion – *significant collaborations in the hottest growth market in cancer diagnostics*

Cracking Cancer's Code with the Telo Platform

Telomere parameters quantified by TELOVIEW®

Healthy cell



Diseased cell



the 3D spatial structure of each telomere is visualized and digitally analyzed. The diseased cell show aggregates, extremely small telomeres, nuclear spaces without telomeres and different telomere numbers

Strongly Derisked Platform

💰 >$30M Canadian Grant Funding

Telo's proprietary Telomere platform supports multiple vertical applications—from oncology diagnostics and MRD monitoring to therapy management and longevity—across cancer and non-cancer indications.

>3000 — **Over 3000 patients evaluated**

>160 — **Validated through over 160 peer reviewed publications**

19 — 19 Patents in Canada, USA & Europe **with longevity up to 2043**

Platform Technology has been developed – future R&D applied to new clinical applications

- Multiple Myeloma (Smoldering, newly diagnosed & MRD)
- Hodgkin's Lymphoma
- Prostate cancer
- Lung cancer
- Neuroblastoma
- Breast cancer
- Myelodysplastic syndromes/acute myeloid leukemia
- Leukemia
- Brain tumor
- Thyroid cancer
- Esophageal cancer
- Gastrointestinal cancer
- Melanoma
- Plasmacytoma
- Cervical cancer
- Alzheimer's disease

Clinical Partners Extensively Evaluated the Platform

HARVARD UNIVERSITY

MAYO CLINIC

Cleveland Clinic

Dana-Farber Cancer Institute

McGill UNIVERSITY



American Journal of Hematology AJH

Three-dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma

Shaji Kumar [1], S Vincent Rajkumar [1], Dragan Jevremovic [1], Robert A Kyle [1], Yulia Shifrin [2], Michelle Nguyen [2], Zahabiya Husain [2], Asieh Alikhah [2], Anita Jafari [2], Sabine Mai [3], Kenneth Anderson [4], Sherif Louis [2]

Affiliations

1 The Mayo Clinic, Rochester, MN, USA.
2 Telo Genomics Corp, Toronto, Ontario, Canada.
3 University of Manitoba, Winnipeg, Manitoba, Canada.
4 Dana Farber Cancer Institute, Boston, Massachusetts, USA.



Telo Genomics Initiate Clinical Trial for Minimal Residual Disease in Multiple Myeloma

June 18, 2025 8:30 AM EDT | Source: **Telo Genomics Corp.**

Toronto, Ontario--(Newsfile Corp. - June 18, 2025) - **Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF)** (the **"Company"** or **"Telo"**), a leader in the development of diagnostic and prognostic tests for human disease through its proprietary 3D analysis of the genomic instability of telomeres, is pleased to announce that it has initiated a multiple myeloma ("MM") clinical trial in collaboration with Cleveland Clinic Cancer Institute, Cleveland, OH. The samples are to be assessed and stratified between minimal residual disease ("MRD") patients that are active or in remission, in a clinical trial of the Company's TeloView MM-MRD assay.

Telo Genomics announced its initial MRD trial in MM on February 22, 2024, in collaboration with McGill University/Jewish General Hospital, Montreal, Canada (NCT05530096). The new collaboration with Cleveland Clinic allows Telo to expand access and recruitment from a broader spectrum of patient groups, including patients receiving new CAR-T therapies that are more prevalent in the USA, and can contribute to expediting the validation of TeloView MM-MRD.

Liquid Biopsy: A Game-Changer

Better than Standard biopsy - Safer, faster, cheaper



- ❑ **Minimally invasive**
- ❑ **Truly representative of the disease**
  (measures not just the biopsied tissue area)
- ❑ **Real-time monitoring**
- ❑ **Lower cost and convenience**

AI is Revolutionizing Cancer Detection

Eliminates pathologist subjectivity, "Automates tedious manual steps"

Automated cell identification: *AI can recognize and classify different cell types with high accuracy.*

Quantitative analysis: *AI can measure features like size, shape, and staining intensity*



Pattern recognition: *AI can spot early signs of disease, such as atypical or malignant cells*

Workflow efficiency: *AI reduces the time pathologists spend on routine tasks*

Standardization: *AI provides consistent results, reducing variability between pathologists*

Capturing the $4.5 B MRD Market opportunity



FDA recognition in April 2024 has allowed MRD to be used in clinical trials as a **surrogate endpoint**, speeding up drug development.

Market Size a & Forecast *

- 2024 Market size: **US$ 2.5 Billion**
- 2030 projected market size: **US$ 4.5 Billion**
- CAGR (2025-2030): 10.1%
- North America: largest market in 2024

Key investment drivers include:

- **Rising cancer incidence**, particularly in hematological malignancies like leukemia, multiple myeloma and lymphoma.
- **Technological advances** in diagnostic tools, including next-generation sequencing (NGS) and digital PCR.
- **Growing demand for personalized medicine**, which uses MRD tests to guide and tailor treatments.

* Grandviewresearch.com

Minimum Residual Disease (MRD) for Multiple Myeloma

Key criteria for extension of the relapse: MRD sensitivity, Ability for easy monitoring, Ability to identify aggressive cells



Sensitivity of current technologies:

Adaptive biotechnologies · sebia · EuroFlow · Binding Site part of Thermo Fisher Scientific

Telo Genomics' technology is 10-100-fold more sensitive
→ delaying cancer recurrence

TELOGENOMICS

Telo Genomics' liquid biopsy test allows easy monitoring → identifying relapse earlier

Telo enables differentiation of aggressive MM cells with a tendency to cause earlier relapse versus less aggressive MM cells

Key Advantages of Telo's MRD Technology

- **Versatile across multiple sample types** — *including liquid biopsy, tissue, and bone marrow.*
- **Enhanced sensitivity** — *detects disease down to* 10^{-7}*, exceeding the industry standard of* 10^{-6} *(Adaptive).*
- **Lower retest rate** — *significant* **reduction** *in retest rate compared to Adaptive assays.*
- **Biological specificity** — *uniquely distinguishes* **viable tumor cells** *from cell-free DNA from dead cells.*
- **Single-cell risk assessment** — *enables identification of* **high-risk, aggressive cells** *versus less aggressive clones.*

MM Clinical Trial Program

TeloView SMM	MAYO CLINIC	**Multiple studies performed & published with Mayo Clinic** to train and validate the SMM risk prediction test for **Telo Genomics' CAP/CLIA** certified lab.
TeloView NDMM	MAYO CLINIC	**Initial study (training) performed & published with Mayo Clinic**, follow-up study in development
TeloView MRD	Hôpital général juif Jewish General Hospital – McGill	Only processing follow-up samples
	Cleveland Clinic	**Ongoing prospective clinical trial. Initial data was presented at Myeloma Canada MRD Summit 2025**
	Polish Myeloma Foundation (part of IMF)	**Retrospective MM MRD trial with multi year follow-up**, Study initiation January 2026 with the goal to publish mid 2026
	French Myeloma Foundation (part of IMF)	**Prospective MM MRD trial with multi year follow-up**, Study initiation January 2026 with the goal to publish Q4 2026 (interim)
	Greek Myeloma Foundation (part of IMF)	**Retrospective MM MRD trial with multi year follow-up**, Study initiation March 2026 with the goal to publish Q3 2026

Alzheimer's: Huge Challenge, Huge Opportunity

- **57M people worldwide have dementia**; most have Alzheimer's.
- Slowly erodes memory and thinking; **6th leading cause of death in the U.S.**
- **No cure yet**—current treatments postpone disease progression.
- **Cases could triple to 150M by 2050**.
- Early detection is tough—**but solving it could change everything**.

Alzheimer's detection made simple with a cheek swab and Teloview®



Results: Control vs. Mild AD



Figure 4. Average telomere number and length, where fluorescence intensity corresponds to telomere length in arbitrary units (a.u.). Telomeric characteristics of mild Alzheimer's disease (AD) patient (red) are compared to those of age- and gender-matched cognitively normal control (grey). The combined analysis of telomere length and number reveals a distinct telomeric profile in mild AD, characterized by significantly shorter telomeres and a slight increase in telomere count relative to controls.

All data from https://www.weforum.org/stories/2025/06/recent-breakthroughs-fight-against-alzheimers-disease/

Business Model

Monetization Opportunities

- **Platform with multiple verticals** that can be independently monetized.
- **Lead focus on MM MRD** with strong clinical and commercial potential.
- **Licensing and partnering opportunities** in oncology and beyond (e.g., prostate, breast).
- **Optional full commercialization** supported by strong, broad IP protection.

Quarterly Milestones



Cap Table & Funding



As of October 27, 2025	
SHARES OUTSTANDING	100.4M
OPTIONS	4.2M
WARRANTS	28.7M
FULLY DILUTED SHARES	133.4M

SHARE PRICE 10/27/25	$0.055CAD
MARKET CAP	$5.5MCAD
BURN RATE	$150KCAD/ MONTH

TELOGENOMICS

Corporate Update

Transforming Cancer Diagnostic with AI and Liquid Biopsy

555 Richmond St West, Toronto, Canada
Info@teloddx.com
647 477 9365